Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

NCT01142661 ·Status: COMPLETED ·Phase: NA

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

NCT02864030 ·Status: COMPLETED ·Phase: PHASE4

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

NCT02061085 ·Status: COMPLETED ·Phase: PHASE2

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

NCT01463891 ·Status: COMPLETED

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer

NCT01669252 ·Status: COMPLETED ·Phase: PHASE2

Loreline Study: Characterization of Long Responders Under Eribuline

NCT03771183 ·Status: COMPLETED

Retroprospective Real Life Observatory of Eribulin

NCT02393287 ·Status: COMPLETED

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

NCT03795012 ·Status: TERMINATED ·Phase: PHASE2

Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer

NCT05302778 ·Status: UNKNOWN

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

NCT01439282 ·Status: COMPLETED ·Phase: PHASE2

Eribulin in Brain Metastases From HER2-negative Breast Cancer

NCT03637868 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

NCT03437083 ·Status: COMPLETED

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

NCT01268150 ·Status: COMPLETED ·Phase: PHASE2

PhII ICb With/Without Erbitux in MBC Pts

NCT00248287 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

NCT01795586 ·Status: COMPLETED ·Phase: PHASE1

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

NCT03245112 ·Status: UNKNOWN

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

NCT01401959 ·Status: COMPLETED ·Phase: PHASE2

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

NCT03430518 ·Status: COMPLETED ·Phase: PHASE1

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

NCT02551263 ·Status: COMPLETED

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

NCT04874025 ·Status: COMPLETED

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

NCT00879086 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

NCT06857305 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

NCT03412955 ·Status: UNKNOWN ·Phase: PHASE2

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

NCT02404506 ·Status: TERMINATED ·Phase: PHASE2

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

NCT02210364 ·Status: COMPLETED ·Phase: PHASE1